Objective: Age, sex, weight loss, lactate dehydrogenase (LDH) level, hemoglobin concentration, stage and ECOG performance status (PS) have been accepted as prognostic factors for patients with small cell lung cancer (SCLC). In our study, we aim to evaluate the relationship between prognostic factors and survival in patients with SCLC.
INTRODUCTION
Small cell lung cancer (SCLC) accounts for approximately 13-20% of bronchogenic carcinomas [1, 2] . History of cigarette smoking is detected in 95% of SCLC [3] . Most cases are diagnosed in patients aged ≥65 years and age has prognostic significance in SCLC [4] . Although it was identified that female sex, ECOG performance status (PS) and LDH level were important prognostic factors in SCLC, survival strongly correlated with stage and treatment received [4, 5] . Without treatment, median survival after diagnosis is 1 to 3 months. However, with combination chemotherapy, it is found as 14 to 16 months for limited stage disease (LSD) and 8 to 11 months for extensive stage disease (ESD) [2, 3, 6] . It is an aggressive tumor that often metastasizes before the primary cancer is diagnosed [7] .
Surgery has a limited role in primary therapy. On the other hand, SCLC is sensitive to chemotherapy and radiotherapy with response rates of greater than 80% in both LSD and ESD, but complete cure is difficult to achieve [3, 8] . The combination of platinum and etoposide is the accepted standard chemotherapeutic regimen. In addition, thoracic concomitant chemoradiotherapy in LSD is also applied [8] . SCLC usually recurs within one year after treatment [7] . In this study, SCLC patients treated and followed-up in the Department of Medical Oncology were retrospectively analyzed. Furthermore, we also evaluated median survival both in LSD and ESD patients and the relationship between median survival and prognostic factors in patients with SCLC.
MATERIAL and METHOD
A total of 106 patients with SCLC followed up from 2005 to 2008 in Dr. Lutfi Kirdar Education and Research Hospital, Department of Medical Oncology were included in this study. Most of the patients were diagnosed with fiberoptic bronchoscopy (74.8%) (other diagnostic tools were mediastinoscopy (7%), transthoracic fine niddle aspiration biopsy (5%), operation (5%), cytology of pleural effusion and liver biopsy). After taking the history and physical examination, patients were grouped according to ECOG PS and underwent chest-X ray and CT of the thorax. Complete blood count, biochemical tests including liver functions tests, LDH, urea and creatinine levels were measured. Based on staging, patients were classified as LSD or ESD. After the end of the second or third and fourth or sixth cycles of chemotherapy regimens, patients were reevaluated by physical examination, complete blood count, biochemical tests and radiological imaging and patients were followed-up every 3 months.
Statistical Methods
Statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA) software. Survival analysis and curves were established according to the KaplanMeier method and compared using the log-rank test. Progression free survival (PFS) was defined as the time from the diagnosis to the last follow-up and the time until relapse. In addition, overall survival (OS) was described as the time from diagnosis to the date of the patient's death or last known contact. Prognostic factors analyzed by univariate analysis were also evaluated with multivariate analysis using the Cox proportional hazards model to predict the risk factors for relapse and survival. Multivariate p values were used to characterize the independence of these factors. A 95% confidence interval (CI) was used to quantify the relationship between survival time and each independent factor. All p values were two-sided in tests and p values less than or equal to 0.05 were considered significant. (Figure 1 ). Overall survival in 1 and 2 years were 58% and 23% respectively. We detected only the stage of disease as a prognostic factor for OS (p=0.001) and PFS (p=0.003) ( Table 2 ).
RESULTS

Patient
DISCUSSION
The most important known cause of SCLC is cigarette smoking, accounting for approximately 95% of cases and is rarely observed in someone who had never smoked [3, 9, 10] . There was a history of smoking about 90.3% of patients with SCLC analyzed in our study. This result was concordance with the literature. Complete evaluation of patients with SCLC consist of history, physical examination, complete blood count, electrolytes, LDH, urea, creatinine, liver function tests, CT of thorax, abdomen and MRI of brain. Also, evaluation of bone metastasis, radionuclide bone scanning is required [1, 8, 11] .
SCLC presence of ipsilateral supraclavicular lymph nodes and ipsilateral pleural effusions with unknown cytological diagnosis. ESD is defined as the presence of overt metastatic disease by imaging [1] [2] [3] 12, 13] . Malignant pleural effusion or contralateral supraclavicular nodes or contralateral hilar nodes are considered to be ESD [9] . The stage of disease is the most important predictor of improvement and survival in SCLC [5] . As it was known that LSD to ESD ratio was 1/1, while new developments are seen in imaging techniques, this ratio changed to 1/3 [12, 14] . [3, 8, 12] . Cancer and Leukemia Group B (CALGB) identified female sex and PS as important predictors of survival both in LSD and ESD. LSD patients older than 60 years had a higher mortality rate than younger patients, but age was not predictive of survival in ESD [15] . Torun et al. [13] reported that stage and PS were major prognostic factors, but there was no relationship between age, alkaline phosphatase level and survival. Although they showed LDH related survival by using univariate analysis, it could not be confirmed by multivariate analysis. In another study, elevated level of LDH in patient with LSD predicted poorer survival relative to those with LDH in normal range. A possible explanation of this relationship may be that, LDH estimates tumor burden in patient with LSD and suggests that LDH identifies occult disease not detected by current staging investigation [6] . Ray et al. [16] documented that weight loss, high LDH level was accepted as prognostic factors for SCLC, but not achieving complete response to treatment. Another study concluded that stage and PS were more predictive than age in the survival of SCLC. Chute et al. [11] documented that male gender, PS<2, and presence of liver metastasis were associated with worse prognosis ESD, and in LSD PS>1, male gender were found to be adverse factors in survival. While we statistically found, by using multivariate analysis, that extensive stage was a prognostic factor associated with worse prognosis but not LDH level, weight loss, age, sex and hemoglobin level in our patients, so only stage of disease had statistically prognostic importance (p=0.001).
Although SCLC is sensitive to chemotherapy, local failure occurred in 50-90% of cases when using chemotherapy as single modality. Addition of radiotherapy to the thorax improves local control and increase survival [9, 12, 14] . Combined modality treatment with concomitant chemoradiotherapy is the current standard of treatment. Two meta-analysis have shown a 5% improvement in 3-year survival rates for patients receiving a combination of chemotherapy and radiotherapy versus receiving chemotherapy alone [8] . Sequential, alternating, concurrent approaches have been tried in integrating radiotherapy and chemotherapy and in early studies no statistically significant difference was found among them, but the Japanese Clinical Oncology Group (JCOG) study showed improvement in overall survival with concurrent therapy in LSD [8] . When platinum etoposide regimens are used, concurrent radiotherapy is superior to sequential radiotherapy [1] . In our patients, we also used combination chemotherapy and radiotherapy sequentially in LSD but not concomitant due to technical problems related to radiotherapy.
Patients with ESD are treated with palliative chemotherapy, whereas patients with LSD are treated with curative intent to achieve a 5-year survival rate of 20% [8, 18] . With standard chemotherapy LSD has a response rate of 80-90% and also a complete clinical response can be achieved in 50-60% of patients. On the other hand, in ESD, chemotherapy is palliative because duration of response is short [9] . Platinum-based chemotherapy remains the mainstay of treatment of both LSD and ESD. Cisplatin and etoposide combination is standard for SCLC and usage of 4 to 6 cycles offer significant survival advantage in patients with SCLC. Randomized studies evaluating the role of maintenance therapy did not relieve any survival advantage for prolonged treatment [8] . The issue of carboplatin versus cisplatin was reviewed in literature who concluded that, carboplatin and etoposide seems to be as effective, but less toxic, than the cisplatin plus etoposide regimen [1, 7, 8, 11] . Because of lower toxicity, the carboplatin included regimen could be preferred for patients with low creatinine clearance and older patients [2, 8, 12] . We used a rate of 87.8% of cisplatin plus etoposide combination for a median 6 cycles as the first line chemotherapy regimen for patients with SCLC. After the end of treatment, about 71.2% CR plus PR were achieved.
The risk of central nervous metastasis developing 2 years after treatment of SCLC is approximately 35-65%. Thus, prophylactic cranial irradiation (PCR) was introduced for responsive LSD [1, 8] . A meta-analysis of efficacy of PCR in 847 patients with LSD and 147 patients with ESD who had complete remission with chemotherapy and radiotherapy demonstrated a 25.3% decrease in incidence of brain metastasis and increase in overall survival of 5.4% in 3 years with PCR [8, 9, 12] . National Comprehensive Cancer Network recommends PCR for patients with either LSD or ESD who achieve complete response [8] . Only 3 patients could be given prophylactic cranial radiation in our study because of technical problems related to radiotherapy.
CONCLUSION
Although SCLC has a high initial response to chemotherapy and radiotherapy, 5-year survival is still 15% to 25% for patients with LSD and less than <1% for patients with ESD. The median survival time is markedly increased from 2 to 3 months in untreated patients to 8 to 16 months in patients treated with chemotherapy. Therefore it is important to define pretreatment prognostic factors that correlate with extent of disease in order to predict responsivity to treatment and survival following diagnosis.
